| 000 | 03429 am a22003613u 4500 | ||
|---|---|---|---|
| 042 | _adc | ||
| 100 | 1 | 0 |
_aDonovan, Killian _eauthor _93106 |
| 700 | 1 | 0 |
_aHerrington, William G. _eauthor _92196 |
| 700 | 1 | 0 |
_aParé, Guillaume _eauthor _93107 |
| 700 | 1 | 0 |
_aPigeyre, Marie _eauthor _93108 |
| 700 | 1 | 0 |
_aHaynes, Richard _eauthor _92234 |
| 700 | 1 | 0 |
_aSardell, Rebecca _eauthor _93109 |
| 700 | 1 | 0 |
_aButterworth, Adam S. _eauthor _93110 |
| 700 | 1 | 0 |
_aFolkersen, Lasse _eauthor _93111 |
| 700 | 1 | 0 |
_aGustafsson, Stefan _eauthor _93112 |
| 700 | 1 | 0 |
_aWang, Qin _eauthor _93113 |
| 700 | 1 | 0 |
_aBaigent, Colin _eauthor _92233 |
| 700 | 1 | 0 |
_aMälarstig, Anders _eauthor _93114 |
| 700 | 1 | 0 |
_aHolmes, Michael V. _eauthor _93115 |
| 700 | 1 | 0 |
_aStaplin, Natalie _eauthor _92197 |
| 245 | 0 | 0 | _aFibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study |
| 260 | _c2023-01-01. | ||
| 500 | _a/pmc/articles/PMC7614195/ | ||
| 500 | _a/pubmed/36719157 | ||
| 520 | _aBACKGROUND: Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding. METHODS: SCALLOP consortium data on 19,195 participants were used to generate an FGF-23 genetic score. Data from 337,448 UK Biobank participants were used to estimate associations between higher genetically-predicted FGF-23 concentration and the odds of any atherosclerotic cardiovascular disease (n=26,266 events), of any non-atherosclerotic cardiovascular disease (n=12,652), and of non-cardiovascular diseases previously linked to FGF-23. Measurements of carotid intima-media thickness and left ventricular mass were available in a subset. Associations with cardiovascular outcomes were also tested in three large case-control consortia: CARDIOGRAMplusC4D (coronary artery disease, n=181,249 cases), MEGASTROKE (stroke, n=34,217), and HERMES (heart failure, n=47,309). RESULTS: We identified 34 independent variants for circulating FGF-23 which formed a validated genetic score. There were no associations between genetically-predicted FGF-23 and any of the cardiovascular or non-cardiovascular outcomes. In UK Biobank, the odds ratio for any atherosclerotic cardiovascular disease per 1-SD higher genetically-predicted logFGF-23 was 1.03 (95% confidence interval [CI] 0.98-1.08), and for any non-atherosclerotic cardiovascular disease was 1.01 (0.94-1.09). The odds ratios in the case-control consortia were 1.00 (0.97-1.03) for coronary artery disease, 1.01 (0.95-1.07) for stroke, and 1.00 (0.95-1.05) for heart failure. In those with imaging, logFGF-23 was not associated with carotid or cardiac abnormalties. CONCLUSION: Genetically predicted FGF-23 levels are not associated atherosclerotic and non-atherosclerotic cardiovascular diseases, suggesting no important causal link. | ||
| 540 | _a | ||
| 540 | _ahttps://creativecommons.org/licenses/by/4.0/Open Access For the purpose of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising. (https://creativecommons.org/licenses/by/4.0/) | ||
| 546 | _aen | ||
| 690 | _aArticle | ||
| 655 | 7 |
_aText _2local |
|
| 786 | 0 | _nClin J Am Soc Nephrol | |
| 856 | 4 | 1 |
_uhttp://dx.doi.org/10.2215/CJN.05080422 _zConnect to this object online. |
| 999 |
_c1003 _d1003 |
||